Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Telescope Innovations Corp ( (TSE:TELI) ) has shared an update.
Telescope Innovations reported fiscal 2025 revenues of $5.8 million, up from $4.4 million a year earlier, alongside an adjusted EBITDA loss of $402,000 as it continued to reinvest heavily in research and commercialization. Operationally, the company advanced its multi-year self‑driving lab development project with Pfizer, secured new commercialization opportunities in Asia including plans to deploy its first self‑driving lab for pharmaceutical development in Korea, delivered record sales and expanded geographic reach for its DirectInject‑LC™ product, and produced battery‑grade lithium sulfide for shipment to battery industry customers in North America and Asia, signaling a pivotal shift from pure development toward broader commercial adoption across multiple end markets.
More about Telescope Innovations Corp
Telescope Innovations Corp. is a chemical technology company that develops scalable manufacturing processes and enabling tools for the pharmaceutical and broader chemical industries. Its portfolio centers on intelligent automation, including flexible robotic platforms and artificial intelligence software, designed to boost experimental throughput, efficiency and data quality, with a stated focus on addressing challenges in health and sustainability.
Average Trading Volume: 76,404
Technical Sentiment Signal: Sell
Current Market Cap: C$18.53M
For an in-depth examination of TELI stock, go to TipRanks’ Overview page.